Nomura Upgrades Dr. Reddy's Laboratories to Buy From Neutral, Cuts Price Target to 1,500 Indian Rupees From 6,499 Indian Rupees
Dr Reddy's Labs Is Maintained at Overweight by Barclays
Dr Reddy's Laboratories Analyst Ratings
Barclays Maintains Dr. Reddy's Laboratories(RDY.US) With Buy Rating, Cuts Target Price to $17
Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,130 From INR1,120, Keeps at Underperform
Dr Reddy's Laboratories Analyst Ratings
BofA Securities Maintains Dr Reddy's Laboratories Ltd(RDY.US) With Buy Rating
Barclays: Maintaining the Dr. Reddy's Laboratories (RDY.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $80.00 to $81.00.
Dr Reddy's Laboratories Analyst Ratings
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $81
Dr Reddy's Laboratories Analyst Ratings
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $70 From $67, Maintains Overweight Rating
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $66 From $69, Reiterates Overweight Rating